Rockville biotech looks for lifeline following restructuring
Rexahn Pharmaceuticals Inc. is standing at a crossroads.
The Rockville biotech announced Tuesday an intention to consider “strategic alternatives” as it cuts staff and searches for ways to extend resources.
Potential moves include a merger or acquisition, reverse merger or other business combination. It could also mean licensing or selling off it s assets. CEO Doug Swirsky declined to comment beyond the company’s press release.
Rexahn (NASDAQ: REXN) is also eliminating two positions and…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Sara Gilgore Source Type: news